宫颈癌免疫治疗的临床研究进展  

Clinical Research Progress of Immunotherapy for Cervical Cancer

作　　者：孙敬兰 戴建荣[1] SUN Jinglan;DAI Jianrong(Department of Gynecology,Suzhou Hospital Affiliated to Nanjing Medical University/Suzhou Municipal Hospital,Suzhou 215000,China)

机构地区：[1]南京医科大学附属苏州医院苏州市立医院妇科,江苏苏州215000

出　　处：《医学综述》2022年第16期3204-3210,共7页Medical Recapitulate

摘　　要：全球女性宫颈癌新发病例逐年上升,且有年轻化趋势,仅靠手术、放疗、化疗这些传统方式已经无法满足复发性/转移性晚期宫颈癌患者延长寿命的愿望。免疫治疗在黑色素瘤、肺癌等肿瘤治疗中表现卓越,目前宫颈癌相关免疫治疗是妇科肿瘤研究的热点,主要包括三大研究方向:治疗性疫苗、免疫检查点抑制剂、免疫细胞改造。目前已知,对复发性/转移性晚期宫颈癌患者进行免疫治疗,可一定程度上延长患者总生存期及无病生存期,有望成为治疗晚期宫颈癌的新方法。The number of new cases of cervical cancer in women around the world is increasing year by year,and there is a younger trend.The traditional methods of surgery,radiotherapy and chemotherapy alone can no longer meet the aspiration of the patients with recurrent/metastatic advanced cervical cancer to prolong their life.In view of the excellent performance of immunotherapy in melanoma,lung cancer and other tumor fields,cervical cancer-related immunotherapy has become the research hotspot of gynecologic tumors.Immunotherapy includes three major research directions:therapeutic vaccines,immune checkpoint inhibitors,and immune cell transformation.According to the published studies,immunotherapy for patients with recurrent/metastatic advanced cervical cancer can prolong the overall survival and disease-free survival to a certain extent,and is expected to become a new method for the treatment of advanced cervical cancer.

关 键 词：宫颈癌 治疗性疫苗 免疫检查点抑制剂 免疫细胞改造 

分 类 号：R737.33[医药卫生—肿瘤]